pembrolizumab (Keytruda)

following a full submission:

pembrolizumab (Keytruda®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.

Recurrence-free survival was significantly longer with pembrolizumab compared with placebo in a phase III study of adolescent and adult patients with completely resected, Stage IIB or IIC melanoma.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Pembrolizumab has previously been accepted for use as monotherapy for the adjuvant treatment of patients with Stage III melanoma and lymph node involvement who have undergone complete resection (SMC2144).